Overview
Physician services provider's Q4 revenue beat analyst expectations
Adjusted EBITDA for Q4 missed analyst expectations
Same-unit revenue growth driven by improved collections and favorable payor mix
Outlook
Pediatrix anticipates 2026 Adjusted EBITDA between $280 mln and $300 mln
Result Drivers
SAME-UNIT REVENUE GROWTH - Driven by improved collections, favorable payor mix, and higher patient acuity, particularly in neonatology
PRACTICE DISPOSITIONS - Net revenue decline due to practice dispositions, partially offset by same-unit revenue growth
PATIENT SERVICE VOLUME DECLINE - Same-unit patient service volumes decreased by 2.7% in Q4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $493.77 mln | $486.23 mln (7 Analysts) |
Q4 Net Income | $33.68 mln | ||
Q4 Adjusted EBITDA | Miss | $65.85 mln | $71.10 mln (7 Analysts) |
Q4 Income from operations | $48.79 mln | ||
Q4 Operating Expenses | $444.98 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $22.00, about 0.1% above its February 18 closing price of $21.97
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago
Press Release: ID:nBw99nhjFa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)